Related Experiment Video
Updated: Jun 6, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Antiretroviral drug development for HIV: challenges for the future
Lawrence R Boone1, George W Koszalka
1Boone Consulting Services LLC, 4801 Abercroft Place, Fuquay-Varina, NC, USA
Current Opinion in Investigational Drugs (London, England : 2000)
|November 16, 2010
Summary
The development of new HIV drugs is shifting focus from blocking replication to targeting latent HIV reservoirs for a functional cure. This requires long-term research investment to overcome treatment limitations and improve patient quality of life.
Area of Science:
- Virology
- Drug Discovery
- Immunology
Background:
- Current HIV therapies effectively suppress viral replication but require lifelong treatment with significant side effects and risk of resistance.
- The pipeline for novel HIV drugs targeting replication is limited, with incremental improvements in existing classes proving commercially unviable.
- Identifying new targets within the HIV replication cycle presents substantial scientific challenges and uncertain risk/reward scenarios for investment.
Discussion:
- The scientific community is advocating a paradigm shift towards eradicating latent HIV reservoirs, which persist despite current antiretroviral therapies.
- Achieving a functional or sterilizing cure for HIV necessitates innovative strategies beyond simple viral load suppression.
- This transition requires sustained commitment and funding, primarily from the National Institutes of Health (NIH), with industry collaboration.
Key Insights:
- The commercial viability of incremental HIV drug improvements is diminishing, signaling a need for fundamentally new approaches.
- Attacking latent HIV reservoirs is proposed as the next critical frontier for achieving a cure.
- Lifelong treatment, side effects, and emerging resistance underscore the urgency for novel HIV interventions.
Outlook:
- Future HIV research must prioritize the development of strategies to eliminate latent viral reservoirs.
- Increased investment in long-term research, potentially through public-private partnerships, is crucial for advancing HIV cure research.
- Developing innovative therapies is essential to prevent infection, enhance the quality of life for infected individuals, and ultimately achieve a cure.
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
02:33Retroviruses
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
00:36Viral Mutations
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...